Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

This study has been terminated.
(Trial discontinued due to apparent lack of response in psoriasis measures. No safety concerns were present)
Information provided by (Responsible Party):
Novo Nordisk A/S Identifier:
First received: December 14, 2010
Last updated: February 3, 2016
Last verified: February 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: January 2011
  Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):